Grünenthal Gmbh and King’s College London have entered into a 24-month collaboration to develop microfluidic culture (MFC) models based on human induced pluripotent stem cells (iPSCs) for pain research.
Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged pranoprofen derivatives reported to be useful for the treatment of pain and eye disorders.
Bacteria inflaming the meninges have developed an immunosuppressive mechanism that contributes to their ability to attack the brain. Researchers found that, by activating pain receptors (nociceptors) to release chemical substances that block an immune cell receptor, Streptococcus pneumoniae and Streptococcus agalactiae deactivated the protective function of macrophages and weakened brain defenses. This, in turn, enabled them to invade the brain.
Jiangsu Nhwa Pharmaceutical Co. Ltd. and Shujing Biopharma Co. Ltd. have synthesized oxaspiro derivatives acting as μ-opioid receptor agonists reported to be useful for the treatment of pain.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro have synthesized N-acylhydrazone acting as sodium channel protein type 9 subunit alpha (SCN9A, Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain.
Medasense Biometrics Ltd. received U.S. FDA marketing authorization for its PMD-200 patient monitor with nociception level index (NOL) technology that monitors patients’ physiological response to pain during surgery. NOL uses a multi-parametric sensor platform combined with artificial intelligence (AI) algorithms to generate a ‘signature of pain’ for patients under anesthesia who are also receiving opioids and other analgesics.
The Biotechnology Innovation Organization (BIO) found in a new study that 77% of clinical programs focused on pain therapeutics five years ago are no longer active and that financings of companies working in the space are lackluster at best. Meanwhile, oncology companies, targeting an overall smaller market, have raised huge sums of venture capital money, $9.7 billion in 2021 vs. pain and addiction companies’ $228 million.
Researchers from Hefei Industrial Pharmaceutical Institute Co. Ltd. presented the discovery and preclinical evaluation of novel multifunctional inhibitors as potential anti-inflammatory and analgesic agents.
